Cell therapy for Parkinson's disease with induced pluripotent stem cells

Rinshō shinkeigaku = Clinical neurology
Asuka Morizane

Abstract

Cell therapy for Parkinson's disease has a history of being applied clinically with aborted embryos as donor source. Efficacy of the therapy under the appropriate condition has been reported. Based on this experience and the advancement of stem cell technology, clinical trials of cell therapy with embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) are going to start soon in several countries. In Japan a physician-initiated clinical trial of iPSC-based therapy for Parkinson's disease has launched since 2018. This trial adopts allogeneic transplantation with a cell line from iPSC stock. This article discusses patient selection, procedure, and risk of the therapy. It also introduces the world's current situation of the cell therapy for Parkinson's disease.

References

Mar 1, 1996·Trends in Neurosciences·C W OlanowT B Freeman
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J H KordowerC W Olanow
Feb 20, 1999·Archives of Neurology·R A HauserC W Olanow
Mar 10, 2001·The New England Journal of Medicine·C R FreedS Fahn
Aug 7, 2001·Journal of Neuropathology and Experimental Neurology·P Hagell, P Brundin
Oct 29, 2002·Annals of Neurology·Yilong MaDavid Eidelberg
Sep 4, 2003·Annals of Neurology·C Warren OlanowThomas B Freeman
Aug 13, 2005·Neurobiology of Disease·Eleonora MariesKathy Steece-Collier
Oct 26, 2005·Brain : a Journal of Neurology·Paola PicciniOlle Lindvall
Apr 9, 2008·Nature Medicine·Jeffrey H KordowerC Warren Olanow
Feb 3, 2009·Neuropsychiatric Disease and Treatment·Emma L LaneStephen B Dunnett
Apr 29, 2009·The Journal of Comparative Neurology·Kathy Steece-CollierEleonora Maries-Lad
Jul 2, 2010·Science Translational Medicine·Marios PolitisPaola Piccini
Sep 18, 2010·Lancet Neurology·Elodie AngotPatrik Brundin
Apr 5, 2011·Nature Methods·Keisuke OkitaShinya Yamanaka
May 26, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Marios PolitisPaola Piccini
Nov 13, 2013·JAMA Neurology·Zinovia KefalopoulouThomas Foltynie
Jan 23, 2014·Journal of Labelled Compounds & Radiopharmaceuticals·Torild WickstrømWilliam Trigg
May 4, 2016·Proceedings of the National Academy of Sciences of the United States of America·Wen LiJia-Yi Li
Sep 24, 2015·NPJ Parkinson's Disease·Roger A BarkerUNKNOWN G-Force PD consortium
Sep 1, 2017·Nature Communications·Asuka MorizaneJun Takahashi
Jun 9, 2018·Stem Cells and Development·Ibon GaritaonandiaRussell Kern

❮ Previous
Next ❯

Citations

Apr 8, 2020·Stem Cells International·Xinchao HuYuming Xu
Apr 14, 2020·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Kenichi Horisawa, Atsushi Suzuki
Feb 5, 2021·Ageing Research Reviews·P A DionísioC M P Rodrigues
Apr 4, 2021·International Journal of Molecular Sciences·Jon LuzuriagaGaskon Ibarretxe
Jan 13, 2022·Neural Regeneration Research·Bochao LiuPaul Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.